Next Generation Sequencing in the Diagnosis of Multiple Myeloma
Frontiers in Bioscience-Scholar · 2026
DOI: 10.31083/fbs44690 ↗At a glance
Übersichtsarbeit in Frontiers in Bioscience-Scholar, 2026. Written by Ikram El Fazazi and 11 co-authors. Institution: Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco. Major MEDLINE topics: Multiple Myeloma, High-Throughput Nucleotide Sequencing. 68 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Multiple myeloma (MM) is a biologically and clinically heterogeneous plasma cell malignancy characterized by clonal expansion in the bone marrow and a highly variable clinical course. Despite major therapeutic advances, MM remains incurable, largely due to the associated genomic complexity, clonal evolution, and the emergence of treatment resistance. In this context, next-generation sequencing (NGS) has emerged as a transformative tool for improving disease characterization, risk stratification, and clinical management. This review summarizes current evidence on the application of NGS technologies, including whole-exome sequencing, whole-genome sequencing, and targeted gene panels—in the diagnosis, prognostic assessment, and monitoring of MM. Genomic profiling has consistently revealed recurrent alterations in key driver genes, copy number abnormalities, and structural variants that underlie disease heterogeneity and influence clinical outcomes. In addition to baseline characterization, NGS enables high-resolution analysis of clonal architecture and evolution, offering critical insights into mechanisms of relapse and therapeutic resistance. Importantly, NGS-based assessment of minimal residual disease (MRD) has demonstrated superior sensitivity compared with conventional techniques, providing a powerful prognostic marker and a promising tool for treatment monitoring and response-adapted strategies. Indeed, by integrating genomic and MRD data, NGS supports a more precise and dynamic approach to patient management. Overall, the growing body of evidence highlights NGS as a central component of precision medicine in multiple myeloma. Continued efforts toward standardization, validation of emerging biomarkers, and clinical implementation of sequencing-guided strategies are expected to enhance personalized treatment further and improve patient outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco.
- Human Pathologies, Biomedicine and Environment Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohammed Ben Abdellah University, 30070 Fez, Morocco.
- Biomedical and Translational Research Laboratory, Faculty of Medicine, Pharmacy, and Dental Medicine of Fez, Sidi Mohamed Ben Abdellah University, 30050 Fez, Morocco.
- Now with The Higher Institute of Nursing Professions and Health Techniques, 30050 Fez, Morocco.
- Department of Internal Medicine and Oncohematology, Sidi Mohammed Ben Abdellah University, CHU Hassan II, 30050 Fez, Morocco.
Cite
APA
El Fazazi, I., Ihlal, H., Ouskri, A., Nmer, S., Washenko, A., El Mouhi, H., Abbassi, M., Ahakoud, M., Bouguenouch, L., Berrady, R., Ouldim, K., & El-Azami-El-Idrissi, M. (2026). Next Generation Sequencing in the Diagnosis of Multiple Myeloma. Frontiers in Bioscience-Scholar. https://doi.org/10.31083/fbs44690
Vancouver
El Fazazi I, Ihlal H, Ouskri A, Nmer S, Washenko A, El Mouhi H, et al. Next Generation Sequencing in the Diagnosis of Multiple Myeloma. Frontiers in Bioscience-Scholar. 2026. doi:10.31083/fbs44690
BibTeX
@article{ElFazazi2026,
author = {El Fazazi, Ikram and Ihlal, Hajar and Ouskri, Amal and Nmer, Samira and Washenko, Angela and El Mouhi, Hinde and Abbassi, Meriame and Ahakoud, Mohamed and Bouguenouch, Laila and Berrady, Rhizlane and Ouldim, Karim and El-Azami-El-Idrissi, Mohammed},
title = {Next Generation Sequencing in the Diagnosis of Multiple Myeloma},
journal = {Frontiers in Bioscience-Scholar},
year = {2026},
doi = {10.31083/fbs44690}
}
EUVIMED